Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK
- 1 December 2010
- journal article
- research article
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 43 (3) , 251-259
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Cost-Effectiveness Analysis: What It Really Means for Transfusion Medicine Decision MakingTransfusion Medicine Reviews, 2009
- Pathogen reduction of blood componentsTransfusion and Apheresis Science, 2008
- Acute lung injury after ruptured abdominal aortic aneurysm repair: The effect of excluding donations from females from the production of fresh frozen plasma*Critical Care Medicine, 2008
- Transfusion-related Acute Lung Injury in the Critically IllAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic modelHealth Technology Assessment, 2006
- Update on pathogen reduction technology for therapeutic plasma: An overviewTransfusion and Apheresis Science, 2006
- Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United StatesVox Sanguinis, 2004
- Cost‐effectiveness of solvent/detergent‐treated fresh‐frozen plasmaVox Sanguinis, 2003
- Cost‐effectiveness of transfusing virus‐inactivatedplasma instead of standard plasmaTransfusion, 1999
- Safety and Cost-effectiveness of Solvent-Detergent—Treated Plasma1994